Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

422
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
422
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

632
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
632
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

919
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
919
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

899
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
899
Teratogenicity01:07

Teratogenicity

3.6K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.6K
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

117
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
117

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Collodion in Erysipelas.

The North-Western medical and surgical journal·2023
Same author

[Potential teratogenicity of modafinil - Conflicting evidence, need for research].

Gynecologie, obstetrique, fertilite & senologie·2023
Same author

Comment on "Maternal use of fluconazole and congenital malformations in the progeny: A meta-analysis of the literature".

Reproductive toxicology (Elmsford, N.Y.)·2021
Same author

Evaluation of a preemptive strategy for BK polyomavirus-associated nephropathy based on prospective monitoring of BK viremia: a kidney transplantation center experience.

Transplantation proceedings·2010
Same author

Clinical and biochemical features of seven adult adrenal ganglioneuromas.

The Journal of clinical endocrinology and metabolism·2010
Same author

Activity and cross-reactivity of antibodies induced in mice by immunization with a group B meningococcal conjugate.

Infection and immunity·2001

Related Experiment Video

Updated: Nov 10, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.5K

[Use of triptans during pregnancy].

M Latour1

  • 1Centre de référence sur les Agents Tératogènes (CRAT), Paris, France; DMU ESPRIT (épidémiologie et biostatistique, santé publique, pharmacie, pharmacologie, recherche, information médicale, thérapeutique et médicaments), Paris, France; GHU, Sorbonne Université - Site Trousseau, AP-HP, 26, avenue du Docteur Arnold Netter, 75571 Paris cedex 12, France.

Gynecologie, Obstetrique, Fertilite & Senologie
|April 5, 2021
PubMed
Summary

Triptans are used for migraine in pregnancy, but concerns exist due to rare fetal deaths. Current analysis does not confirm a direct triptan effect, supporting their use as a second-line treatment.

Keywords:
5HT1-B5HT1-DGrossessePregnancySerotoninSérotonineTriptans

More Related Videos

Author Spotlight: Advancing Labor Management Through Electromyometrial Imaging for Understanding Uterine Contractions
08:07

Author Spotlight: Advancing Labor Management Through Electromyometrial Imaging for Understanding Uterine Contractions

Published on: May 26, 2023

1.5K
Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

442

Related Experiment Videos

Last Updated: Nov 10, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.5K
Author Spotlight: Advancing Labor Management Through Electromyometrial Imaging for Understanding Uterine Contractions
08:07

Author Spotlight: Advancing Labor Management Through Electromyometrial Imaging for Understanding Uterine Contractions

Published on: May 26, 2023

1.5K
Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
05:13

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes

Published on: February 28, 2025

442

Area of Science:

  • Obstetrics and Gynecology
  • Neurology
  • Pharmacology

Background:

  • Triptans are commonly prescribed for migraine management during pregnancy.
  • Concerns have arisen regarding potential vasoconstrictive effects and rare adverse fetal outcomes, including fetal death and intrauterine growth restriction.

Purpose of the Study:

  • To evaluate the safety and efficacy of triptans for treating migraine in pregnant individuals.
  • To analyze existing data regarding rare fetal deaths and intrauterine growth restrictions in the context of maternal triptan use.

Main Methods:

  • Review of recent case reports and existing literature on triptan use during pregnancy.
  • Analysis of data to assess the correlation between triptan administration and reported fetal complications.

Main Results:

  • Recent reports suggest rare instances of fetal death and intrauterine growth restriction associated with triptan use.
  • Current data analysis does not establish a definitive causal link between triptans and these adverse fetal outcomes.

Conclusions:

  • Triptans remain a recommended second-line treatment option for migraine attacks during pregnancy.
  • Continued cautious use of triptans is advised under normal conditions and at any stage of gestation, pending further research.